Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Eyes Booster Dose Trial Launch in January
October 22, 2021
- Mundipharma Japan Set to Cut into High Production Costs, Boost Profitability to Lure Investments: President
October 22, 2021
- Taiwan OKs Opdivo-Chemo Combo for Gastric Cancer: Ono
October 21, 2021
- Meiji Pharma Rolls Out ATLL Drug Hiyasta in Japan
October 21, 2021
- Sumitomo Dainippon, BehaVR Seal Deal on VR Digital Therapeutics
October 20, 2021
- Chugai, Oncolys to Call Off License Deal for Telomelysin
October 20, 2021
- Japan Joins Global PIII Schizophrenia Program for GlyT1 Inhibitor: BI
October 20, 2021
- Veklury Now Available in Normal Distribution Channel in Japan
October 19, 2021
- Lenvima/Keytruda Gets European Panel Nod for RCC, Endometrial Carcinoma
October 19, 2021
- JCR’s Hunter Syndrome Drug Earns PRIME Tag in Europe
October 19, 2021
- Alfresa to Introduce Digital-Driven Deliveries at All Offices by August 2024; Test Run Showing Good Results
October 18, 2021
- Pfizer Japan, Health Tech Startup Join Hands in AI-Powered Support for OAB Patients
October 18, 2021
- Pfizer/Mylan/Viatris to Discontinue 18 Generic Drugs
October 15, 2021
- Shionogi President Urges Govt to Stockpile Infectious Disease Drugs
October 14, 2021
- MSD, Maruho Warn of Ivermectin Prescribing for COVID-19, Stressing Such Use Not Approved
October 14, 2021
- Abraxane Supply to Continue until Mid-December without Possible Stockouts: Taiho
October 13, 2021
- Japan Drug Makers Prepping to Launch New Organization to Solve Challenges in Digital Health
October 13, 2021
- Lack of Management Response, Tight Manufacturing Plans to Blame in Choseido Issue: Report
October 12, 2021
- Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
- Sales Reps’ Detailing Activities Decrease by 3.4% in August: Intage
October 12, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…